DIUX.F Stock Overview
A diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Diaceutics PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.37 |
| 52 Week High | UK£1.37 |
| 52 Week Low | UK£1.05 |
| Beta | 0.36 |
| 1 Month Change | 0% |
| 3 Month Change | 2.18% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -28.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| DIUX.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 2.8% |
| 1Y | n/a | -5.6% | 24.5% |
Return vs Industry: Insufficient data to determine how DIUX.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how DIUX.F performed against the US Market.
Price Volatility
| DIUX.F volatility | |
|---|---|
| DIUX.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 9.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DIUX.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DIUX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 151 | Peter Keeling | www.diaceutics.com |
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network.
Diaceutics PLC Fundamentals Summary
| DIUX.F fundamental statistics | |
|---|---|
| Market cap | US$89.68m |
| Earnings (TTM) | US$7.42k |
| Revenue (TTM) | US$27.10m |
Over9,999x
P/E Ratio3.3x
P/S RatioIs DIUX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIUX.F income statement (TTM) | |
|---|---|
| Revenue | UK£21.90m |
| Cost of Revenue | UK£2.77m |
| Gross Profit | UK£19.13m |
| Other Expenses | UK£19.13m |
| Earnings | UK£6.00k |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.000071 |
| Gross Margin | 87.37% |
| Net Profit Margin | 0.027% |
| Debt/Equity Ratio | 0% |
How did DIUX.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/05 06:48 |
| End of Day Share Price | 2023/08/08 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Diaceutics PLC is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hayley Palmer | Canaccord Genuity |
| Colin Smith | Capital Access Group |
| Oliver Juggins | Capital Access Group |